Compare Enveric Biosciences Inc (ENVB) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Schlumberger NV — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Schlumberger NV trades at $48.97 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 10689.7× Enveric Biosciences Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Schlumberger NV for 99 Days on average.
| ENVB | SLB | |
|---|---|---|
Market Cap | $6.80M | $72.69B |
Volume | 64,867 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $10.80 | $60.10 |
52-Week Low | $1.27 | $31.72 |
Typical Hold Time | 14 Days | 99 Days |
Enterprise Value | -$1.49M | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
SLB trades at $47.96, down 4.08% in the last session, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats and a robust $35.71B revenue base, though 2025 net income declined to $3.37B. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility, supporting analyst optimism with an 84.85% buy rating and $64.58 consensus price target.
SLB presents a compelling value opportunity with significant upside to analyst targets, driven by expanding international contracts and solid cash flow generation. Key risks include oil price volatility and execution challenges in new projects. The stock's current technical weakness may offer an attractive entry point for long-term investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
